Price
No data yet.
Social Signal Score
Analyst Ratings
46 analystsRevenue
$4.14B-25.54%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard D. Francis
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 32,008
- Beta
- 0.80
- Country
- IL
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 0.88
Financials
Revenue
$4.14B-25.5%Net Income
$-576.00M-265.5%EBITDA
$-19.00M-101.4%Free Cash Flow
$307.00M-75.2%EPS (diluted)
$-0.49-240.0%Shares Outstanding (diluted)
1.18B+20.0%Operating Expenses
$1.28BCash & Debt
$3.65BReturn of Capital
$0.00Revenue by Segment (annual)
$17.26BDividend per Share
$0.09Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $17.26B | $1.41B | $1.23 |
| 2024 | $16.54B | $-1.64B | $-1.45 |
| 2023 | $15.85B | $-559.00M | $-0.50 |
| 2022 | $14.93B | $-2.45B | $-2.20 |
| 2021 | $15.88B | $417.00M | $0.38 |
| 2020 | $16.66B | $-3.99B | $-3.64 |
| 2019 | $16.89B | $-999.00M | $-0.92 |
| 2018 | $18.85B | $-2.15B | $-2.11 |
| 2017 | $22.39B | $-16.27B | $-16.01 |
| 2016 | $21.90B | $329.00M | $0.07 |
| 2015 | $19.65B | $1.59B | $1.84 |
| 2014 | $20.27B | $3.06B | $3.58 |
| 2013 | $20.31B | $1.27B | $1.49 |
| 2012 | $20.32B | $1.96B | $2.25 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from TEVA's reported EPS growth of -4.5% a year over 13 years.
- EPS in 5 years
- $0.97
- Implied price
- $24.37
- Return from $39.64
- -9.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $12.12 — -69.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 21 | 25 | 29 | 33 |
|---|---|---|---|---|---|
| -14.5% | -24.8% | -21.6% | -18.8% | -16.3% | -14.1% |
| -9.5% | -20.4% | -17.0% | -14.0% | -11.4% | -9.1% |
| -4.5% | -16.0% | -12.4% | -9.3% | -6.5% | -4.1% |
| 0.5% | -11.6% | -7.8% | -4.5% | -1.6% | 0.9% |
| 5.5% | -7.2% | -3.2% | 0.2% | 3.2% | 6.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
98+52.85%Social Signal Score
Mentions (33)
- Newsglobenewswire.com·4d ago·Positive
…h Tourette Syndrome PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome. Presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS) in Seoul, South Korea (October 4–8, 2026), the data inc…
View source ↗ - Newsglobenewswire.com·4d ago·Positive
… Pediatric Patients PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the Journal of Child Neurology published a comprehensive review examining dopamine pathways in Tourette syndrome and the therapeutic potential of ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome.1,2 The re…
View source ↗ - Newsbusinesswire.com·5d ago·Negative
…iosimilar Candidates INCHEON, Korea & TEL AVIV, Israel--(BUSINESS WIRE)-- #Fasenra--Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizumab), and SB44, a biosimilar candidate referen…
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer.
View source ↗ - Newszacks.com·6d ago·Negative
Teva's Branded Drugs Take Center Stage in Its Growth Strategy Teva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.
View source ↗ - Newsglobenewswire.com·7d ago·Negative
…t), a Biosimilar to Xgeva® (denosumab) TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA™ (denosumab-adet) as a biosimilar to Xgeva® (denosumab). DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents w…
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2026 financial results on Tuesday, November 3, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Teva Releases Q3 2026 Aide Memoire TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the “Investors” page on its website.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
View source ↗ - Newsmarketbeat.com·13d ago·Negative
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings Teva Pharmaceutical Industries NYSE: TEVA is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard Francis said at the BofA Global Healthcare Conference.
View source ↗ - Newsseekingalpha.com·14d ago·Positive
Teva Pharmaceutical Industries Limited (TEVA) Presents at U.S. All Stars Conference Transcript Teva Pharmaceutical Industries Limited (TEVA) Presents at U.S. All Stars Conference Transcript
View source ↗ - Newsmarketbeat.com·14d ago·Neutral
Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline Teva Pharmaceutical Industries NYSE: TEVA Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company with a growing innovative medicines portfolio, while maintaining and expanding its generics operations.
View source ↗ - Newsglobenewswire.com·17d ago·Negative
… in Older Patients PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choice experiment highlighting preferred healthcare provider (HCP) treatment attributes when selecting a VMAT2 inhibitor for the treatment of TD in older patients (aged ≥55 years). The new findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
…d Healthcare Costs PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating treatment continuity, healthcare resource utilization (HCRU) and clinical outcomes among adults with schizophrenia and bipolar I disorder (BD-I) treated with UZEDY (risperidone) extended-release injectable suspension. The results demonstrate how UZEDY helps patients with schizoph…
View source ↗ - Newsglobenewswire.com·17d ago·Positive
…ophrenia in Adults PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new olanzapine LAI (TEV-'749) post hoc data from the pivotal SOLARIS Phase 3 trial as well as analyses supporting treatment switch strategies. The SOLARIS data highlighted the acute and long-term durability, efficacy and safety of TEV-'749 as a once-monthly subcutaneous long-acting injectab…
View source ↗ - Newsschaeffersresearch.com·19d ago·Neutral
Most Active Options Report: FPS, TEVA, AFL These three stocks are seeing some of the most unusual options volume today
View source ↗ - Newsmarketbeat.com·21d ago·Neutral
Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform Teva Pharmaceutical Industries NYSE: TEVA CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded medicines, innovation, generics and biosimilars, as well as improved financial flexibility.
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Teva Pharmaceutical Industries Limited (TEVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Teva Pharmaceutical Industries Limited (TEVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·21d ago·Negative
Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars Teva Pharmaceutical Industries NYSE: TEVA said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics business, an expanding biosimilars portfolio and a strengthened balance sheet.
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy PARSIPPANY, N.J. and TEL AVIV, Israel, Sept.
View source ↗ - Newsglobenewswire.com·26d ago·Negative
…Successful Pricing of $4.9 billion (Equivalent) Senior Notes TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the “Notes”). Teva expects to use the net proceeds from the offering, together with cash on hand, (i) to fund the redemptions of certain existing notes as further set out below (the “Conditional Redempt…
View source ↗ - Newsglobenewswire.com·29d ago·Neutral
Teva Announces Launch of Offering of Senior Notes TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denominated Senior Notes (the “Euro Notes”) and Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”) and Teva Pharmaceutic…
View source ↗ - Newsschaeffersresearch.com·32d ago·Positive
Outperforming Pharma Stock Still Has Upside Potential Teva Pharmaceuticals Industries (NYSE:TEVA) is moving 2.9% lower to trade at $36.41, pulling back from its Aug. 27, nearly nine-year high of $38.36.
View source ↗ - Newsseekingalpha.com·33d ago·Positive
Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study Transcript Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study Transcript
View source ↗ - Newsmarketbeat.com·33d ago·Neutral
Teva's TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study Teva Pharmaceutical Industries NYSE: TEVA reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company saying the treatment met its primary endpoint and showed statistically significant effects on key measures of intestinal damage.
View source ↗ - Newsreuters.com·34d ago·Negative
Teva's immune disorder drug meets main goal in mid-stage trial Israeli drugmaker Teva Pharmaceutical Industries , said on Wednesday its experimental drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the main goal of a mid-stage trial.
View source ↗ - Newsglobenewswire.com·34d ago·Negative
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential Teva reports positive Phase 2a results for Teva-discovered TEV '408, showing significant prevention of gluten-induced intestinal damage in celiac disease.
View source ↗ - Newsglobenewswire.com·35d ago·Negative
…ARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When finalized, this agreement will support continued investment in scientific innovation and pharmaceutical manufacturing capabilities. “Teva appreciates the opportunity to wor…
View source ↗ - Newszacks.com·35d ago·Neutral
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment.
View source ↗ - Newsglobenewswire.com·39d ago·Negative
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Agreement is part of a court-supervised sale process with BioXcel Therapeutics, Inc. and remains subject to bankruptcy court approv
View source ↗ - Newszacks.com·46d ago·Neutral
TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome Teva's ecopipam secures FDA priority review for pediatric Tourette syndrome, potentially bringing the first new therapy in over a decade.
View source ↗ - Newszacks.com·47d ago·Neutral
Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock? Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.
View source ↗ - Newsglobenewswire.com·48d ago·Negative
…ARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ecopipam, with a targeted action (PDUFA) date late in the first quarter of 2027. Ecopipam is a first-in-class investigational therapy for the treatment of pediatric patients with Tourette syndrome. This milestone advan…
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $0.71 per share
Typical surprise +6.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$0.02 vs $0.08miss
- Wed, Apr 29$0.53 vs $0.50beat
- Wed, Jan 28$0.96 vs $0.65beat
- Wed, Nov 5$0.78 vs $0.68beat
- Wed, Jul 30$0.66 vs $0.63beat
- Wed, May 7$0.52 vs $0.47beat
Estimates and results for TEVA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TEVA officers and directors.
- Bought
- —
- Sold
- $42.0m
0 trades
32 trades
- Savage Briansold
- Savage Briansold
- Savage Briansold
- Mignone Robertosold
- Weiss Amirsold
- Weiss Amirsold
- Satchi-fainaro Ronitsold
- Lippman Evansold
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Dec 2, 2020 (19d later)Buy$15,001 - $50,000
- Donna Shalalahouse · FL27 · disclosed May 15, 2020 (8d later)Sell$1,001 - $15,000
- David Eugene Pricehouse · NC04 · disclosed Jul 11, 2019 (22d later)Sell$1,001 - $15,000
- Patty Murraysenate · WA · disclosed Jun 22, 2017 (7d later)Sell$1,001 - $15,000
- Angus Kingsenate · ME · disclosed Nov 10, 2016 (22d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.